U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 751 - 760 of 13362 results

Status:
Possibly Marketed Outside US
Source:
UK NHS:Camphene
Source URL:

Class (Stereo):
CHEMICAL (MIXED)


Conditions:

Camphene is a bicyclic monoterpene, a Plant Derived Monoterpene, which possessed antitumor activity. This was found in vivo by inhibiting subcutaneous tumor growth of highly aggressive melanoma cells in a syngeneic model, suggesting a promising role of this compound in cancer therapy. In addition was shown, that camphene lowered cholesterol and triglycerides (TG) in the plasma of hyperlipidemic rats without affecting HMG-CoA reductase activity. And was suggested, that camphene upregulated Sterol regulatory element-binding proteins (SREBP-1) expression and microsomal triglyceride transfer protein (MTP) inhibition was likely to be a probable mechanism whereby camphene exerts its hypolipidemic effect.
Status:
Possibly Marketed Outside US
First approved in 2020

Class (Stereo):
CHEMICAL (ACHIRAL)


Diflubenzuron is a direct-acting insecticide normally applied directly to plants or water. Diflubenzuron, besides its use in agriculture, horticulture and forestry against larvae of Lepidoptera, Coleoptera, Diptera, Hymenoptera, and in public health against larvae of mosquitoes, is used as a veterinary drug for the treatment of sea lice infestations in Atlantic salmon. Diflubenzuron acts by interference with the synthesis of chitin. It is reported that public exposure to diflubenzuron through either food or drinking-water is negligible.
Status:
Possibly Marketed Outside US
Source:
NCT00680121: Phase 4 Interventional Completed Alcoholism
(2008)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Benfotiamine is a derivative of vitamin B1. It was developed in Japan specifically to treat Korsakoff's syndrome and patented in the United States in 1962, but never became popular. It has been in use as a widely used prescription drug in Europe since 1978 to treat diabetes and is available at many vitamin shops in the United States. It has been licensed for use in Germany since 1993 under the trade name Milgamma. (Combinations with pyridoxine or cyanocobalamin are also sold under this name). It is prescribed there for treating sciatica and other painful nerve conditions. It is marketed as a medicine and/or dietary supplement, depending on the respective Regulatory Authority. Unfortunately apparent evidences from human studies are scarce and especially endpoint studies are missing. Benfotiamine has proven to affect glucose metabolic process through various mode of actions, and plays a part in obstructing age-associated glycation end products (AGEs). Benfotiamine reduces the extra biosynthesis and accumulation of a number of glucose metabolites, including glyceraldeyde-3-phosphate and dihydroxyacetone phosphate. Elevated levels of those glucose intermediates function as a trigger to most of the mechanisms accountable for hyperglycemia-caused cell damage. Benfotiamine increases tissue amounts of thiamine diphosphate, consequently growing transketolase activity and producing a significant decrease in glucose metabolites and precursors to AGEs. Up to now, two of the most effective AGE inhibitors in living microorganisms would be the Vitamin B1 derivative, benfotiamine and also the Vitamin B6 derivative, pyridoxamine. Additionally, benfotiamine has long been proven to lessen NF-kB activity, therefore restricting the over-production from the harmful superoxide toxin. Excess superoxide production may partly hinder a vital enzyme in glucose metabolic process, glyceraldehyde-3-phosphate dehydrogenase, directing glucose metabolites from glycolysis in to the major glucose-driven signaling paths that cause hyperglycemic damage. Theoretically, overdose with benfotiamine should cause menopausal flashes, bluish skin (because of rapid utilization of oxygen), tingling, and difficulty breathing, but used, this merely has not happened.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Natural bicyclic sesquiterpenes, β‐caryophyllene (BCP) and β‐caryophyllene oxide (BCPO), are present in a large number of plants worldwide. Both BCP and BCPO possess significant anticancer activities, affecting growth and proliferation of numerous cancer cells. BCP is a phytocannabinoid with strong affinity to cannabinoid receptor type 2 (CB2 ), but not cannabinoid receptor type 1 (CB1 ). In opposite, BCP oxidation derivative, BCPO, does not exhibit CB1/2 binding, thus the mechanism of its action is not related to endocannabinoid system (ECS) machinery. It is known that BCPO alters several key pathways for cancer development, such as mitogen-activated protein kinase (MAPK), PI3K/AKT/mTOR/S6K1 and STAT3 pathways. In addition, treatment with this compound reduces the expression of procancer genes/proteins, while increases the levels of those with proapoptotic properties. Either as a pure substance or a component of plant essential oils, BCPO was found to exhibit antiinflammatory, antioxidant, antiviral, anticarcinogenic, and analgesic properties. β-caryophyllene oxide evidenced potent cytotoxic activity against HepG2, AGS, HeLa, SNU-1, and SNU-16 cells, with IC50 values of 3.95, 12.6, 13.55, 16.79, and 27.39 uM, respectively.
Status:
Possibly Marketed Outside US
Source:
Folinex by Vivera Pharmaceuticals, Inc.
Source URL:
First approved in 2020
Source:
Folinex by Vivera Pharmaceuticals, Inc.
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)